Company / SG&A Expense
Jade Biosciences, Inc. SG&A Expense History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$21.4M
FY2024
5-year range
$949.0K / $21.4M
FY2020-FY2024
Trend
+24.5%
vs FY2023
Sector context
#194 of 212
Health Care
What the data says
Among 212 Health Care companies, Jade Biosciences, Inc. is in the top 8% for sg&a expense. SG&A Expense has increased for 4 consecutive years, from $949,000 in FY2020 to $21M in FY2024.
Based on SEC 10-K filings.
$21M in FY2024 with a 3-year CAGR of +38.6%.
Increased from $15M to $21M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +38.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 212This company $21.4M Sector average $722.9M
▼
-97.0% below sector average
Key checks
Key Insights
- Jade Biosciences, Inc.'s sg&a expense has grown for 4 consecutive years.
- 3-year CAGR of +38.6%, indicating consistent growth.
- In FY2024, sg&a expense increased 24.5% year-over-year.
- Ranks #194 out of 212 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.03 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $21.4M | +24.5% |
| FY2023 | $17.2M | +17.6% |
| FY2022 | $14.6M | +81.9% |
| FY2021 | $8.0M | +746.7% |
| FY2020 | $949.0K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026